Strength gains within 14 days — clinically proven
A statistically significant 15% improvement in bench press 1RM was demonstrated at just 14 days in RipFACTOR®'s first gold-standard RCT — an extremely rapid strength onset for a botanical ingredient. At 8 weeks, upper body strength improved up to 55% and lower body up to 31% in the ultra-performance group. These results occurred in resistance-trained males familiar with exercise, making them particularly credible.
Muscle gains exceeding double the exercise volume
In the second RCT, subjects taking RipFACTOR® at the performance dose showed strength and endurance gains comparable to the placebo group doing twice the exercise. At the ultra-performance dose, gains significantly exceeded the double-exercise placebo group — demonstrating that RipFACTOR® supplements exercise adaptation rather than simply adding stimulant-type acute effects.
Free testosterone elevation and anabolic hormone support
Both clinical studies confirmed improvements in testosterone:cortisol ratio favoring anabolism. A 19% increase in total testosterone and 30–40% increase in free testosterone at the ultra-performance dose represents meaningful hormonal support for muscle building and recovery — a genuine differentiator from other botanical muscle ingredients without hormonal evidence.
Endurance and time to exhaustion
Beyond strength, RipFACTOR® improved muscle endurance (repetitions to failure) and time to exhaustion — benefits relevant for both strength athletes seeking more reps and endurance athletes needing sustained output. This dual strength/endurance profile reflects the Mangifera indica bark's vascular and mitochondrial support mechanisms.
mTOR activation and testosterone:cortisol ratio optimization
Sphaeranthus indicus bioactives (sesquiterpene lactones, flavonoids) and Mangifera indica bark polyphenols work synergistically to activate mTOR/p70S6K muscle protein synthesis signaling, improve testosterone biosynthesis efficiency (Leydig cell function), and suppress cortisol-mediated protein catabolism. This combination shifts the anabolic:catabolic hormonal balance toward muscle growth while simultaneously providing direct intracellular anabolic signaling — explaining why RipFACTOR® outperforms double exercise volume in clinical assessment.
Randomized, double-blind, placebo-controlled 8-week trial of RipFACTOR® (650 mg/day) in resistance-trained males. Primary endpoints: 1RM bench press and leg press, muscle endurance, muscle size.
40 resistance-trained males aged 18–40 with ≥6 months training experience. 8-week RCT.
Significant increases in upper and lower body strength at 14 days (p<0.0001). At 8 weeks: 55% upper body strength improvement, 31% lower body. Muscle size and endurance improvements. Free testosterone and testosterone:cortisol ratio improved. No adverse effects.
8-week RCT with efficiency model design comparing RipFACTOR® at two doses vs. placebo and placebo with double exercise volume.
Larger sample including both trained and untrained subjects. Novel double-exercise placebo comparison design.
Performance dose matched double-exercise placebo group outcomes. Ultra-performance dose significantly exceeded double-exercise placebo group for strength and endurance. Free testosterone 30–40% above baseline. 10–15% total testosterone increase. Confirms RipFACTOR® supplements exercise adaptation.